• 1.

    Ng JH, Iyer NG, Tan MH, Edgren G. Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study. Head Neck. 2017;39(2):297–304.

    PubMed 

    Google Scholar
     

  • 2.

    Li Y, Zhao Z, Liu X, Ju J, Chai J, Ni Q, et al. Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. Cancer Med. 2017;6(5):1002–13.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 3.

    Riemann M, Knipfer C, Rohde M, Adler W, Schuster M, Noeth E, et al. Oral squamous cell carcinoma of the tongue: prospective and objective speech evaluation of patients undergoing surgical therapy. Head Neck. 2016;38(7):993–1001.

    PubMed 

    Google Scholar
     

  • 4.

    Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002;360(9340):1131–5.

    PubMed 

    Google Scholar
     

  • 5.

    Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer. 2005;103(9):1843–9.

    PubMed 

    Google Scholar
     

  • 6.

    Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 7.

    Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 8.

    Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045–52.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 9.

    Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14(13):1295–306.

    PubMed 

    Google Scholar
     

  • 10.

    Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21(19):3647–50.

    PubMed 

    Google Scholar
     

  • 11.

    Kattan MW, Gönen M, Jarnagin WR, DeMatteo R, D’Angelica M, Weiser M, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247(2):282–7.

    PubMed 

    Google Scholar
     

  • 12.

    Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2012;118(3):660–9.

    PubMed 

    Google Scholar
     

  • 13.

    Yang L, Takimoto T, Fujimoto J. Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma. BMC Cancer. 2014;14:654.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 14.

    Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79-84.

    PubMed 

    Google Scholar
     

  • 15.

    Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):971–8.

    PubMed 

    Google Scholar
     

  • 16.

    Li W, Tao L, Zhang L, Xiu D. Prognostic role of lymphocyte to monocyte ratio for patients with pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:3391–7.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 17.

    Tan D, Fu Y, Tong W, Li F. Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: a meta-analysis. Int J Surg. 2018;55:128–38.

    PubMed 

    Google Scholar
     

  • 18.

    Mao Y, Chen D, Duan S, Zhao Y, Wu C, Zhu F, et al. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int. 2018;18:201.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 19.

    Sollie S, Santaolalla A, Michaud DS, Sarker D, Karagiannis SN, Josephs DH, et al. Serum immunoglobulin G is associated with decreased risk of pancreatic cancer in the Swedish AMORIS Study. Front Oncol. 2020;10:263.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 20.

    Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.

    PubMed 

    Google Scholar
     

  • 21.

    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.

    PubMed 

    Google Scholar
     

  • 22.

    Lu Z, Yan W, Liang J, Yu M, Liu J, Hao J, et al. Nomogram based on systemic immune-inflammation index to predict survival of tongue cancer patients who underwent cervical dissection. Front Oncol. 2020;10:341.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 23.

    Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503.

    PubMed 

    Google Scholar
     

  • 24.

    Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81.

    PubMed 

    Google Scholar
     

  • 25.

    Furukawa K, Kawasaki G, Naruse T, Umeda M. Prognostic significance of pretreatment lymphocyte-to-monocyte ratio in patients with tongue cancer. Anticancer Res. 2019;39(1):405–12.

    PubMed 

    Google Scholar
     

  • 26.

    Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55.

    PubMed 

    Google Scholar
     

  • 27.

    Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 28.

    Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–91.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93(3):273–8.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 30.

    Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2012;124(1):92–7.

    PubMed 

    Google Scholar
     

  • 31.

    Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005;14(2):425–31.

    PubMed 

    Google Scholar
     

  • 32.

    Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362(10):875–85.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 33.

    Lin S, Wang Y, Wang X, Yan B, Lou W, Di W. Serum immunoglobulin G N-glycome: a potential biomarker in endometrial cancer. Ann Transl Med. 2020;8(12):748.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 34.

    Yi CH, Weng HL, Zhou FG, Fang M, Ji J, Cheng C, et al. Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma. Oncoimmunology. 2015;4(12):e1011503.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 35.

    Vučković F, Theodoratou E, Thaçi K, Timofeeva M, Vojta A, Štambuk J, et al. IgG glycome in colorectal cancer. Clin Cancer Res. 2016;22(12):3078–86.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 36.

    Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65–79.

    PubMed 

    Google Scholar
     

  • 37.

    Kessler A, Sollie S, Karagiannis SN, Walldius G, Hammar N, Van Hemelrijck M. Serum IgG is associated with risk of melanoma in the Swedish AMORIS study. Front Oncol. 2019;9:1095.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 38.

    Sun W, Cheng M, Zhuang S, Chen H, Yang S, Qiu Z. Nomograms to predict survival of stage IV tongue squamous cell carcinoma after surgery. Medicine (Baltimore). 2019;98(26):e16206.


    Google Scholar
     

  • 39.

    Saenthaveesuk P, Yang L, Zeng B, Xu M, Young S, Liao G, et al. Development and validation of multiparametric MRI-based nomogram for predicting occult metastasis risk in early tongue squamous cell carcinoma. BMC Cancer. 2021;21(1):408.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 40.

    Mair M, Nair D, Nair S, Malik A, Mishra A, Kannan S, et al. Comparison of tumor volume, thickness, and T classification as predictors of outcomes in surgically treated squamous cell carcinoma of the oral tongue. Head Neck. 2018;40(8):1667–75.

    PubMed 

    Google Scholar
     

  • 41.

    Balasubramanian D, Subramaniam N, Missale F, Marchi F, Dokhe Y, Vijayan S, et al. Predictive nomograms for oral tongue squamous cell carcinoma applying the American Joint Committee on Cancer/Union Internationale Contre le Cancer 8th edition staging system. Head Neck. 2021;43(4):1043–55.

    PubMed 

    Google Scholar
     

  • 42.

    Huang F, Xu G, Du H. A new nomogram for predicting overall survival and assisting postoperative adjuvant treatment decision-making in stage II oral tongue squamous cell carcinoma: a surveillance, epidemiology and end results (SEER) database analysis. J Oral Maxillofac Surg. 2021. https://doi.org/10.1016/j.joms.2021.04.010.

    Article 
    PubMed 

    Google Scholar
     

  • 43.

    Chang B, He W, Ouyang H, Peng J, Shen L, Wang A, et al. A prognostic nomogram incorporating depth of tumor invasion to predict long-term overall survival for tongue squamous cell carcinoma with R0 resection. J Cancer. 2018;9(12):2107–15.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 44.

    Mascitti M, Zhurakivska K, Togni L, Caponio VCA, Almangush A. Addition of the tumour-stroma ratio to the 8th edition American Joint Committee on Cancer staging system improves survival prediction for patients with oral tongue squamous cell carcinoma. Histopathology. 2020;77(5):810–22.

    PubMed 

    Google Scholar
     

  • 45.

    Jiang Q, Tang A, Long S, Qi Q, Song C, Xin Y, et al. Development and validation of a nomogram to predict the risk of occult cervical lymph node metastases in cN0 squamous cell carcinoma of the tongue. Br J Oral Maxillofac Surg. 2019;57(10):1092–7.

    PubMed 

    Google Scholar
     

  • 46.

    Graupp M, Schaffer K, Wolf A, Vasicek S, Weiland T, Pondorfer P, et al. C-reactive protein is an independent prognostic marker in patients with tongue carcinoma—a retrospective study. Clin Otolaryngol. 2018. https://doi.org/10.1111/coa.13102.

    Article 
    PubMed 

    Google Scholar
     

  • 47.

    Abbate V, Dell’Aversana Orabona G, Salzano G, Bonavolontà P, Maglitto F, Romano A, et al. Pre-treatment Neutrophil-to-Lymphocyte Ratio as a predictor for occult cervical metastasis in early stage (T1–T2 cN0) squamous cell carcinoma of the oral tongue. Surg Oncol. 2018;27(3):503–7.

    PubMed 

    Google Scholar
     

  • 48.

    Wu CN, Chuang HC, Lin YT, Fang FM, Li SH, Chien CY. Prognosis of neutrophil-to-lymphocyte ratio in clinical early-stage tongue (cT1/T2N0) cancer. Onco Targets Ther. 2017;10:3917–24.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 49.

    Shimazaki R, Takano S, Satoh M, Takada M, Miyahara Y, Sasaki K, et al. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cell Oncol (Dordr). 2021. https://doi.org/10.1007/s13402-021-00614-z.

    Article 

    Google Scholar
     

  • 50.

    Peppas I, George G, Sollie S, Josephs DH, Hammar N, Walldius G, et al. Association of serum immunoglobulin levels with solid cancer: a systematic review and meta-analysis. Cancer Epidemiol Prev Biomark. 2020;29(3):527–38.


    Google Scholar
     

  • 51.

    Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol. 2009;158(Suppl 1):43–50.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 52.

    Riihilä P, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, et al. Complement component C3 and complement factor B promote growth of cutaneous squamous cell carcinoma. Am J Pathol. 2017;187(5):1186–97.

    PubMed 

    Google Scholar
     

  • 53.

    Kim SH, Lee MJ, Hwang HK, Lee SH, Kim H, Paik YK, et al. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: a pilot study. Cancer Biomark. 2019;24(3):335–42.

    PubMed 

    Google Scholar
     

  • 54.

    Afshar-Kharghan V. The role of the complement system in cancer. J Clin Investig. 2017;127(3):780–9.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 55.

    Ajona D, Ortiz-Espinosa S, Pio R. Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment. Semin Cell Dev Biol. 2019;85:153–63.

    PubMed 

    Google Scholar
     

  • 56.

    Ling M, Murali M. Analysis of the Complement System in the Clinical Immunology Laboratory. Clin Lab Med. 2019;39(4):579–90.

    PubMed 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)